NCT01042795View on ClinicalTrials.gov

Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy

PHASE2TerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

April 30, 2012

Study Completion Date

January 31, 2013

Conditions
Urothelial CarcinomaBladder Cancer
Interventions
DRUG

Sunitinib

Sunitinib 37.5 mg daily X 16 weeks

Trial Locations (1)

48109

University of Michigan, Ann Arbor

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Michigan

OTHER